CommercialCoverageMedium impact
06.02.29g, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)
Independence Blue Cross·Cardiothoracic Surgery, Transplant Surgery·Pharmacy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued policy 06.02.29g regarding AlloMap™ Molecular Expression Testing for heart transplant rejection coverage. This is a recent policy reissuance effective March 5, 2025. The billing team must review the full policy text to identify any coverage, authorization, or coding changes that may affect claims processing for this specialty transplant diagnostic test.
Action Required
By March 5, 2025: Billing team must obtain and review the complete policy text from the provided URL to identify specific coverage criteria, prior authorization requirements, and applicable billing codes for AlloMap testing. Update billing system rules, encounter templates, and prior authorization workflows accordingly. Coordinate with cardiothoracic surgery/transplant teams to ensure compliance. Without this review, claims for AlloMap testing may be denied or delayed.